Asset profile
Pirepemat (IRL752)
Small molecule
Evidence outlook · lead readout
NCT05258071 · Parkinson Disease
The lead readout missed its primary endpoint. The grade and rationale below record what the trial was designed to show and what it found.
NCT05258071: The trial randomized participants to two pirepemat doses or placebo and used quadruple blinding, with 104 participants enrolled. Its clinical primary endpoint—change in fall frequency—was not statistically significantly better with 600 mg pirepemat than placebo, so the findings provide well-controlled but inconclusive evidence of benefit.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.